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Objectives. This study evaluates the hypothesis that in patients
with syncope of unknown origin, inducible ventricular arrhyth-
mias are specific arrhythmias and therefore should be appropri-
ately treated.
Background. Although syncope is a common clinical entity, the
evaluation and treatment of patients with syncope without a clear
etiology are not well defined. Many patients with syncope of
undetermined origin undergo invasive electrophysiologic evalua-
tion. Abnormalities of the sinus node, prolongation of conduction
times or inducible arrhythmias found at these evaluations are
usually assumed to be the cause of syncope and are therefore
treated. However, whether tachyarrhythmias are truly the cause of
syncope, and whether treatment of these tachyarrhythmias can
prevent recurrent syncope and arrhythmic death, is unknown.
Methods. This study included 50 consecutive patients with
syncope of undetermined origin, ventricular tachyarrhythmias at
electrophysiologic evaluation and treatment with an implantable
cardioverter-defibrillator.
Results. Ventricular stimulation led to sustained monomorphic
ventricular tachycardia in 36 patients, nonsustained ventricular
tachycardia in 5 and ventricular fibrillation in 9. Over a 23 6
15-month (mean 6 SD) follow-up period, 18 patients received
appropriate implantable cardioverter-defibrillator shock. Actuar-
ial probability of appropriate therapy was 22% at 1 year and 50%
at 3 years. Recurrent syncope was seen in five patients, three of
whom had appropriate defibrillator detections at the time of
syncope. Four patients died (sudden death in one, congestive
heart failure in two).
Conclusions. In patients with syncope of undetermined origin
and inducible ventricular tachyarrhythmias, appropriate implant-
able cardioverter-defibrillator therapy is common at follow-up.
Sudden cardiac death is uncommon. This low incidence of sudden
cardiac death and high incidence of appropriate defibrillator
therapy support the current practice of using implantable
cardioverter-defibrillators in patients with syncope of unknown
origin and inducible ventricular arrhythmias.
(J Am Coll Cardiol 1997;29:370–5)
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Syncope is a common clinical complaint, representing up to
3% of emergency room visits and up to 6% of hospital
admissions (1–3). In up to 50% of patients, no diagnosis can be
made (2,4,5). Because of the frequent difficulty in determining
the etiology of syncope and the potentially serious nature of
arrhythmias, electrophysiologic testing was introduced as part
of the evaluation in selected patients with syncope of unknown
origin. Electrophysiological test results were found (6) to be
abnormal in 20% to 75% of patients with syncope of unknown
origin. The highest yield was found in patients with structural
heart disease or electrocardiographic (ECG) abnormalities
(6). Ventricular arrhythmias account for up to 50% of the
electrophysiologic abnormalities identified in patients with
syncope of unknown origin (7–21). Before the widespread use
of implantable cardioverter-defibrillators, patients with syn-
cope and inducible ventricular tachyarrhythmias were primar-
ily treated pharmacologically (6). More recently, inducible
ventricular tachyarrhythmias refractory to pharmacologic ther-
apy in patients with syncope have become an accepted indica-
tion for implantation of a cardioverter-defibrillator (22). How-
ever, there are limited data demonstrating that patients with
syncope and inducible ventricular tachyarrhythmias have an
increased risk of spontaneous ventricular tachyarrhythmias.
The natural history (and therefore specificity of inducible
arrhythmias) of untreated patients with syncope and inducible
ventricular arrhythmias is unknown. Although studies in
untreated patients cannot be performed, implantable
cardioverter-defibrillators provide the opportunity to examine
the incidence of ventricular arrhythmias in the absence of
antiarrhythmic agents. The present study focused on a group of
patients with syncope, a nondiagnostic noninvasive workup,
inducible ventricular arrhythmias and an implantable
cardioverter-defibrillator. We hypothesized that these patients
would have a high recurrence of ventricular arrhythmias.
Therefore, we evaluated the outcome and specificity of induc-
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ible ventricular arrhythmias in this patient group and assessed
the appropriateness of implantable cardioverter-defibrillators
therapy in these patients.
Methods
Study patients. The study included consecutive patients
from January 1991 to December 1995 who presented with
syncope or presyncope, had inducible ventricular arrhythmias
at electrophysiologic evaluation and were treated with implant-
able cardioverter-defibrillators. Patients with sudden cardiac
death or spontaneous sustained ventricular tachyarrhythmias
were excluded. Patients received a complete noninvasive
workup, including history and physical examination, routine
blood tests, electrocardiography, echocardiography and 24 h of
ambulatory ECG monitoring. Abnormalities found on nonin-
vasive testing that could explain the patient’s syncope or
ventricular tachycardia (VT) .30 beats on prolonged ECG
monitoring excluded the patient from the study.
Electrophysiologic evaluation. The initial drug-free elec-
trophysiologic study was performed in the fasting, nonsedated
state. All drugs with antiarrhythmic activity had been discon-
tinued for at least 5 drug half-lives. Sinus node evaluation
consisted of the measurement of sinus node recovery time at
three cycle lengths (600, 500 and 400 ms) and measurement of
sinoatrial conduction time. Premature atrial stimulation was
performed to define the presence of dual-atrioventricular
(AV) node physiology and to assess for atrial arrhythmias.
Programmed ventricular stimulation included single and dou-
ble ventricular extrastimuli during sinus rhythm and three basic
drive cycle lengths, followed by triple extrastimuli during sinus
rhythm and one drive cycle length (23). Our protocol for
patients with syncope of unknown origin included programmed
extrastimuli at the right ventricular apex and did not include
testing during isoproterenol infusion. Sustained monomorphic
VT (SMVT) was defined as VT .30 s or requiring termination
because of hemodynamic compromise. Nonsustained VT
(NSVT) was defined as VT lasting $10 beats. Ventricular
fibrillation (VF) was defined as an arrhythmia of ventricular
origin with a cycle length ,220 ms requiring cardioversion.
Treatment. Patients with inducible ventricular arrhythmias
underwent electrophysiologic-guided serial antiarrhythmic
drugs trials performed in an attempt to identify an efficacious
drug. Those patients with an efficacious drug found and who
were discharged with this drug therapy without an implantable
cardioverter-defibrillator were excluded from the study. By
definition, all patients included in our study had treatment
with an implantable cardioverter-defibrillator. Pharmacologic
therapy in our study group was reserved for those patients
with frequent NSVT, frequent implantable cardioverter-
defibrillator shocks or atrial arrhythmias.
Clinical follow-up. After hospital discharge, the patients
were followed up at regular intervals by their referring cardi-
ologist and at our arrhythmia center every 3 months. Any
symptoms of syncope, arrhythmia recurrence or implantable
cardioverter-defibrillator discharge were noted and evaluated.
Evaluation in those patients with implantable cardioverter-
defibrillators with stored electrograms and RR intervals con-
sisted of full interrogation and recovery of the episode.
Statistical analysis. All continuous variables are reported
as mean value 6 SD. Log rank survival tests were used to
determined statistically significant (p , 0.05) differences of
categoric variables. Continuous variables were analyzed using
Cox proportional hazards models. Cox proportional hazards
models were used to estimate relative risks. Thirty-one clinical
variables were analyzed to assess predictors of recurrent
arrhythmias, recurrent syncope and total mortality. These
variables included age and type and presence of structural
heart disease, New York Heart Association (NYHA) heart
failure class, severity of coronary artery disease, ejection
fraction, type of induced arrhythmia and discharge with a
beta-adrenergic blocking or antiarrhythmic agent. All variables
were initially analyzed separately; multivariate analysis was
then performed for the variables that achieved statistical
significance. Kaplan-Meier curves were constructed for syn-
cope, appropriate implantable cardioverter-defibrillator ther-
apy and survival.
Results
Patients. During the study duration, a total of 283 patients
underwent electrophysiologic testing for syncope or presyn-
cope of unknown origin. Of these patients, 66% had structural
heart disease. At electrophysiologic testing, 82 patients had an
inducible ventricular arrhythmia. A total of 50 of these patients
received an implantable cardioverter-defibrillator and thus met
our entry criteria. Of the remaining 32 patients, 15 were given
antiarrhythmic agents (amiodarone in 4, other antiarrhythmic
agents in 11); 6 patients underwent ablative procedures (sur-
gical resections in 4, radiofrequency ablation in 2); VT was
noninducible after coronary artery bypass graft surgery in 2
patients; 2 patients underwent orthotopic heart transplanta-
tion; and 7 patients (all with VF during triple extrastimuli with
tight coupling intervals) were not treated. Of the 50 patients
with an implantable cardioverter-defibrillator, 42 presented
with syncope, and the remaining 8 with presyncope (40 men, 10
women; mean age 59 6 14 years, range 28 to 80). Structural
heart disease was present in 46 patients, with coronary artery
disease in 33 and idiopathic dilated cardiomyopathy in 7. In
addition, three patients had hypertrophic cardiomyopathy, two
Abbreviations and Acronyms
AV 5 atrioventricular
ECG 5 electrocardiographic, electrocardiogram
NSVT 5 nonsustained ventricular tachycardia
NYHA5 New York Heart Association
SMVT 5 sustained monomorphic ventricular tachycardia
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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had arrhythmogenic right ventricular dysplasia, one had con-
genital heart disease, and one had a benign cardiac tumor.
Noninvasive evaluation. All patients had a baseline ECG
and admission blood work and underwent prolonged ECG
monitoring. Baseline ECG abnormalities were common and
included 9 patients with first-degree AV block and 13 with
bundle branch blocks. Prolonged ECG monitoring demon-
strated NSVT in 26 patients (mean 8 6 6 beats, range 2 to 25).
Signal-averaged ECG abnormalities were present in 17 of 27
patients who underwent this test. Mean left ventricular ejec-
tion fraction was 36 6 14% (range 10% to 49%). No patient
had significant aortic stenosis.
Electrophysiologic evaluation. At electrophysiologic test-
ing, three patients had prolongation of sinus node function
recovery ($1.4 s). The mean HV interval was 58 6 17 ms; the
HV interval was prolonged ($90 ms) in four patients. Ven-
tricular stimulation resulted in SMVT in 36 patients, repro-
ducible symptomatic NSVT in 5 and VF in 9 (Table 1). Mean
cycle length of the induced monomorphic VT was 2406 42 ms.
Only 1 patient had an induced arrhythmia (SMVT) with one
extrastimulus, whereas 33 had their arrhythmia (SMVT in 23,
NSVT in 4, VF in 6) induced with double extrastimuli and 16
with triple extrastimuli (SMVT in 12, NSVT in 1, VF in 3).
Serial antiarrhythmic drug testing (mean 1.6 6 0.7 drugs) was
performed in 48 patients.
Treatment. All patients underwent cardioverter-defibrillator
implantation. Event recording capability was present in 33 of
these implantable cardioverter-defibrillators. Patients with
non-event recording implantable cardioverter-defibrillators
were treated earlier in the series. Concomitant coronary artery
bypass graft surgery was performed in nine patients. Antiar-
rhythmic agents were used at the time of discharge in 18
patients. The indication for antiarrhythmic therapy was atrial
fibrillation in 4 patients and frequent NSVT in the remaining 14.
Follow-up. All patients were followed up by their referring
physician and at our arrhythmia center. During a mean
follow-up period of 236 15 months (range 1 to 56), 18 patients
had 36 appropriate implantable cardioverter-defibrillator dis-
charges defined as syncope or presyncope preceding defibril-
lator shock or ventricular tachyarrhythmia documented by
event recorders (Fig. 1). Of the 33 patients with event recorder
implantable-cardioverter defibrillators, 9 had appropriate im-
plantable cardioverter-defibrillator discharges. The event re-
corders showed VT in seven patients with a mean cycle length
of 282 6 39 ms (range 240 to 360) and VF in two. Of the 17
patients without event recorder implantable cardioverter-
defibrillators, a total of 9 had implantable cardioverter-
defibrillator discharges preceded by syncope or presyncope.
There was no statistical difference between arrhythmia recur-
rence in patients with and without event recorders. Actuarial
analysis showed that the risk of appropriate implantable
cardioverter-defibrillator discharges was 22% at 1 year, 32% at
2 years, 50% at 3 years and 85% at 4 years (Fig. 1).
Recurrent syncope was seen in five patients. Three of the
five patients had implantable cardioverter-defibrillator dis-
charges or detections of ventricular arrhythmias during their
syncopal event. Two others had no detection of tachyarrhyth-
mias by their implantable cardioverter-defibrillators. One of
these patients was thought to have had a seizure, whereas the
other patient’s syncopal event was undiagnosed.
Four patients died (congestive heart failure in two at 2 and
17 months; sepsis at 25 months in 1; sudden death at 26 months
in 1). The sudden death occurred in a patient with severe
coronary artery disease who was found dead at home. His
implantable cardioverter-defibrillator was not interrogated af-
ter his death.
Statistical analysis. Of the 31 variables evaluated (see
Methods), the only statistically significant predictor of appro-
priate implantable cardioverter-defibrillator discharge was a
shorter cycle length of induced arrhythmia (233 vs. 252 ms)
during electrophysiologic testing (p 5 0.03) (Table 2). Trends
toward significance were seen in patients with inducibility at an
earlier stage of ventricular stimulation (p 5 0.06), Q waves on
the admission ECG (p 5 0.07) and discharge without antiar-
rhythmic therapy (p 5 0.09). Those patients discharged with
antiarrhythmic agents had a 1- and 2-year therapy incidence of
10% and 18% versus 28% and 44% in those discharged
without antiarrhythmic agents. Presentation with syncope or
presyncope, etiology of heart disease, duration of spontaneous
NSVT, left ventricular ejection fraction and type of induced
Table 1. Electrophysiologic Study Results
No. of
Extrastimuli
Induced Arrhythmia (no. of pts)
SMVT NSVT VF
1 1
2 23 4 6
3 12 1 3
NSVT 5 nonsustained ventricular tachycardia; pts 5 patients; SMVT 5
sustained monomorphic ventricular tachycardia; VF 5 ventricular fibrillation.
Figure 1. Kaplan-Meier life-table curve demonstrating high frequency
of appropriate implantable cardioverter-defibrillator therapy in pa-
tients with syncope of unknown origin, inducible ventricular arrhyth-
mias and treatment with implantable cardioverter-defibrillators. Ap-
propriate therapy is defined as therapy preceded by syncope or
presyncope (in patients with nonevent recording implantable
cardioverter-defibrillators) or RR intervals and electrograms consis-
tant with VT or VF.
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arrhythmia were not significant predictors of appropriate
implantable cardioverter-defibrillator therapy. Of the 36 pa-
tients with SMVT at baseline electrophysiologic testing, 14 had
appropriate therapy. One of five patients with NSVT at
electrophysiologic testing and three of nine patients with VF
had an appropriate shock (Table 3).
With only one sudden death, no predictors of this event can
be identified. Similarly, with the low event rates of recurrent
syncope and all-cause mortality, predictors of these events are
less reliable. Significant predictors of syncope recurrence were
seen in patients with chronic AF (p 5 0.03), lower left
ventricular ejection fraction (p 5 0.03) and concomitant
coronary artery bypass graft surgery (p 5 0.04). Significant
predictors of all-cause mortality were previous coronary artery
bypass graft surgery (p 5 0.01), a higher NYHA congestive
heart failure (p 5 0.01) and Canadian Cardiovascular Society
anginal class (p 5 0.01) and chronic AF (p 5 0.04) (Table 4).
Trends for increased mortality were seen with Q waves on the
ECG (p 5 0.08) and discharge with a beta-blocker (p 5 0.09).
Discussion
There have been only limited previous reports of long-term
follow-up of patients with syncope of unknown origin, induc-
ible ventricular tachyarrhythmias at electrophysiologic testing
and treatment with implantable cardioverter-defibrillators.
This population offers a unique opportunity to evaluate the
clinical strategy of electrophysiologic testing in patients with
unexplained syncope and the efficacy of implantable
cardioverter-defibrillator therapy in patients with inducible
ventricular arrhythmias. Most of the previously published
series of electrophysiologic testing in syncope of unknown
origin have had a limited number of patients with inducible
ventricular arrhythmias. Follow-up in the group of patients
with ventricular arrhythmias is often not separated from the
patients that are found to have bradyarrhythmias or supraven-
tricular arrhythmias. In fact, the present study is (to our
knowledge) the largest series of patients with syncope, induc-
ible ventricular tachyarrhythmias at electrophysiologic testing
and treatment of any type.
Previous studies: electrophysiologic protocols and inci-
dence of ventricular arrhythmias. Studies of electrophysi-
ologic testing in patients with syncope of unknown origin show
up to a 53% incidence of ventricular tachyarrhythmias (6).
Marked variability of inducibility is seen and is most likely
attributable to patient selection and ventricular stimulation
protocol. Series of syncope of unknown origin with a higher
degree of structural heart disease generally have higher induc-
ibility rates (7,9,10,17). Within each series, patients with struc-
tural heart disease have a higher incidence of inducibility (6).
The ventricular stimulation protocol is of prime importance for
the sensitivity and specificity of induced arrhythmias. In pa-
tients with previously documented SMVT, sensitivities of 60%
to 80% are seen with single and double extrastimuli (24–26)
and 80% to 95% with the addition of a third extrastimulus
(10,25,27). The true specificity of ventricular stimulation is
more difficult to ascertain, but it is generally thought that the
induction of SMVT is relatively specific (24,26,28). With more
aggressive protocols, VF and polymorphic VT become more
common and are thought to be nonspecific, induced arrhyth-
mias (10,25). The induction of VF is generally accepted as an
appropriate end point only in those patients with a high
suspicion of clinical VF (29–31).
Previously published series of syncope of unknown origin
have used ventricular stimulation protocols of double
(7,9,11,13,19,20,32,33) and triple extrastimuli (8,10,12,14–
17,21). In series using double extrastimuli, ventricular arrhyth-
mias were seen in 7% to 36% of patients (mean 19%). In series
using triple extrastimuli, ventricular arrhythmias were seen in
9% to 53% of patients (mean 33%). Many series included VF
as a positive result of electrophysiologic testing, and these
Table 2. Predictors of Appropriate Implantable Cardioverter-
Defibrillator Therapy
Variable p Value RR
Shorter cycle length of induced arrhythmia 0.03 1.17/10 ms*
Fewer extrastimuli to induce arrhythmia 0.07 0.36
Q waves on admission ECG 0.07 0.43
Discharge without AAD 0.09 0.39
SAECG abnormalities 0.11 4.6
Left ventricular ejection fraction 0.60 0.99
Etiology of heart disease 0.77 0.99




Event recording ICD or not 0.94 0.99
*Relative risk (RR) of 1.17 for each 10-ms change in cycle length. AAD 5
antiarrhythmic drug;ECG5 electrocardiogram; ICD5 implantable cardioverter-
defibrillator; SAECG 5 signal-averaged ECG.




Induced Arrhythmia (no. of pts)
SMVT NSVT VF
1 1/1
2 9/23 1/4 3/6
3 4/12 0/1 0/3
Abbreviations as in Table 1.
Table 4. Predictors of All-Cause Mortality
Variable p Value
Higher NYHA congestive heart failure class 0.01
Higher CCS anginal class 0.01
Previous CABG 0.01
Presenting arrhythmia of atrial fibrillation 0.04
Q waves on admission ECG 0.07
Discharge on beta-blockers 0.08
CABG 5 coronary artery bypass graft surgery; CCS 5 Canadian Cardiovas-
cular Society; ECG 5 electrocardiogram; NYHA 5 New York Heart Association.
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patients were treated in the same manner as those with SMVT
or NSVT.
Our protocol for electrophysiologic testing in patients with
syncope of undetermined origin includes triple extrastimuli in
sinus rhythm and at one basic cycle length drive train (23). This
protocol is similar to the protocol that many laboratories
presently use (17,21). In our study, patients with inducible
arrhythmias with fewer extrastimuli exhibited a trend for
increased appropriate implantable cardioverter-defibrillator
discharge (Table 2).
Previous studies: follow-up of patients with inducible ar-
rhythmias. Previous follow-up data for the patients with syn-
cope, a nondiagnostic, noninvasive workup and inducible ven-
tricular arrhythmias at electrophysiologic testing are limited.
The largest series of these patients to date was reported by
Click et al. (15) in 1987. In that group of 112 patients
presenting with syncope and bundle branch block, 46 had
inducible ventricular arrhythmias with triple extrastimuli dur-
ing ventricular pacing (SMVT in 25, NSVT in 19, VF in 2). All
patients in the inducible ventricular tachyarrhythmia cohort
were treated with antiarrhythmic agents or ablative operation.
With a mean 30-month follow-up period, sudden cardiac
deaths in the inducible ventricular arrhythmia group occurred
frequently (11 patients). Seventeen additional patients had
recurrent syncope, and four had recurrent SMVT. Bass et al.
(16), in 1987, also reported high sudden cardiac death rates (14
of 35) in patients with ventricular arrhythmias found at elec-
trophysiologic testing performed for syncope of undetermined
origin. In that study, no difference in outcome was seen on the
basis of rhythm (SMVT, NSVT or VF) induced at electrophysi-
ologic testing. In contrast to the previous studies, Olshansky et
al. (13) found a lower incidence of sudden death (3 of 28) in
syncopal patients with inducible ventricular arrhythmias. Other
smaller studies (8–10,17,20,33) have demonstrated a variable
percent of sudden cardiac death (0% to 17%) during follow-up
in the cohort with syncope of undetermined origin found to
have ventricular tachyarrhythmias at electrophysiologic testing.
Only two small series (18,21) have reported treatment with an
implantable cardioverter-defibrillator. In these two series, a
total of 7 of 11 patients treated with implantable cardioverter-
defibrillators had appropriate therapy.
In our patients with syncope and inducible ventricular
arrhythmias, we found a 50% incidence of appropriate im-
plantable cardioverter-defibrillator shocks at 3 years of follow-
up, which suggests a high incidence of ventricular arrhythmia
recurrence. This finding is similar to the ventricular arrhythmia
recurrence rate found in patients who received an implantable
cardioverter-defibrillator after presenting with cardiac arrest
or SMVT (34–36). In our series, the incidence of sudden
cardiac death was low (2%), which is similar to or lower than
that in patients who present with cardiac arrest or SMVT
(34–36). However, in the previously described large series of
patients with syncope and inducible arrhythmias, the incidence
of sudden cardiac death ranged from 11% to 40% (13,15,16).
The low sudden cardiac death rate in our patient cohort and
the high incidence of appropriate implantable cardioverter-
defibrillator therapy suggest that the implantable cardioverter-
defibrillator may be effective in saving lives in patients with
syncope and inducible ventricular arrhythmias. Whether im-
plantable cardioverter-defibrillator therapy truly reduces over-
all mortality in this group of patients can only be answered with
a prospective, randomized trial. However, only the Canadian
Implantable Defibrillator Study (CIDS) (37) includes patients
with syncope of unknown origin and inducible ventricular
arrhythmias. Neither the Antiarrhythmics Versus Implantable
Defibrillators (AVID) (38) nor the Cardiac Arrest Study
Hamburg (CASH) (39) includes patients with syncope of
unknown origin and inducible ventricular arrhythmias. There-
fore, prospective, randomized data for this group of patients
will be limited.
Patients with induced VF. The treatment of patients with
inducible VF and syncope of unknown origin is controversial.
During the time period of our study, 16 patients with syncope
of unknown origin had inducible VF at electrophysiologic
testing, 9 of whom had implantation of a cardioverter-
defibrillator. Of these nine patients, seven had runs of NSVT
or nonsustained VF preceding their sustained VF. Three of the
patients with inducible VF had appropriate implantable
cardioverter-defibrillator discharges. The seven patients with
inducible VF who did not receive an implantable cardioverter-
defibrillator had VF induced with tight coupling intervals with
three extrastimuli, and only one had reproducible NSVT or
VF. Our finding that VF induced with double extrastimuli may
be associated with arrhythmia recurrence is consistent with
other series of syncope of unknown origin demonstrating a
high rate of recurrent syncope and sudden death in patients
with inducible VF (16,21). It is possible that inducible VF in
the patient population presenting with syncope is not as
nonspecific as has been previously suggested.
Limitations of the study. Limitations to our study include
the retrospective analysis of patient outcomes. Inclusion of
patients without event recording implantable cardioverter-
defibrillators (n 5 17) and therefore reliance on symptoms
before implantable cardioverter-defibrillator shock to classify
discharge as appropriate are additional limitations. Finally, the
use of antiarrhythmic agents in 36% of our patients could
affect implantable cardioverter-defibrillator discharge inci-
dence.
Conclusions. Patients with unexplained syncope and induc-
ible ventricular arrhythmias at electrophysiologic testing have a
high incidence of appropriate implantable cardioverter-
defibrillator therapy during follow-up. The high level of appro-
priate therapy argues for the specificity of electrophysiologic
testing in this patient subgroup; however, the sensitivity of
electrophysiologic testing cannot be determined from the
present study. Sudden cardiac death rates were low in this
cohort treated with implantable cardioverter-defibrillators.
This low sudden cardiac death rate and high appropriate
implantable cardioverter-defibrillator discharge rate support
the current clinical practice of implanting cardioverter-
defibrillators in patients with syncope of unknown origin and
inducible ventricular arrhythmias.
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